Overview

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

Status:
Not yet recruiting

Trial end date:
2028-01-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, open label, non-inferiority, randomized controlled clinical study. The aim of this study is to evaluate the efficacy and safety of a pegylated liposomal doxorubicin + cyclophosphamide followed by docetaxel plus trastuzumab and pertuzumab (PLD + C + HP followed by THP) regimen compared with a docetaxel + carboplatin plus trastuzumab and pertuzumab (TCbHP) regimen in the neoadjuvant treatment of HER-2-positive breast cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Collaborator:

CSPC Ouyi Pharmaceutical Co., Ltd.

Treatments:

Carboplatin
Cyclophosphamide
Docetaxel
Doxorubicin
Liposomal doxorubicin
Pertuzumab
Trastuzumab